SI
FSTX

Sofinnova Investments’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Sofinnova Investments’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-47,412
Closed -$2.29M – 72
2018
Q3 		$2.29M Buy
+47,412
New +$2.37M 0.2% 51

Other funds holding FSTX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TA
Tiedemann Advisors New York $2.33B AUM 15.56% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Sofinnova Investments's FSTX Position: Q4 2018 in Review

Sofinnova Investments sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q4 2018, closing a stake of 47,412 shares — an estimated $2.29M sold.

Sofinnova Investments first reported a position in FSTX in Q3 2018 and held it in 1 quarter. The position peaked at $2.29M in Q3 2018. 57 funds tracked by Wall St. Rank hold FSTX as of Q4 2018.

  • Sofinnova Investments reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Sofinnova Investments sold 47,412 F-star Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $2.29M.
  • Sofinnova Investments first reported a position in F-star Therapeutics, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • Sofinnova Investments's F-star Therapeutics, Inc. Common Stock position peaked at $2.29M in Q3 2018.
  • 57 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Sofinnova Investments's 13F filing for Q4 2018, filed 14 Feb 2019.